Report Detail
Global Multivalent Vaccines Market Insights, Forecast to 2025
- RnM3048961 |
- 05 March, 2019 |
- Global |
- 128 Pages |
- QYResearch |
- Pharma & Healthcare
The global Multivalent Vaccines market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Multivalent Vaccines market based on company, product type, end user and key regions.
This report studies the global market size of Multivalent Vaccines in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Multivalent Vaccines in these regions.
This research report categorizes the global Multivalent Vaccines market by top players/brands, region, type and end user. This report also studies the global Multivalent Vaccines market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc. (U.S.)
Johnson & Johnson (U.S.)
MedImmune, LLC (U.S.)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (U.S.)
Panacea Biotec (India)
Market size by Product
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Market size by End User
Pediatrics
Adults
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Multivalent Vaccines market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Multivalent Vaccines market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Multivalent Vaccines companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Multivalent Vaccines submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Multivalent Vaccines are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Multivalent Vaccines market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Multivalent Vaccines Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Multivalent Vaccines Market Size Growth Rate by Product
- 1.4.2 Conjugate Vaccines
- 1.4.3 Inactivated and Subunit Vaccines
- 1.4.4 Live Attenuated Vaccines
- 1.4.5 Toxoid Vaccines
- 1.4.6 Recombinant Vaccines
- 1.5 Market by End User
- 1.5.1 Global Multivalent Vaccines Market Size Growth Rate by End User
- 1.5.2 Pediatrics
- 1.5.3 Adults
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Multivalent Vaccines Market Size
- 2.1.1 Global Multivalent Vaccines Revenue 2014-2025
- 2.1.2 Global Multivalent Vaccines Sales 2014-2025
- 2.2 Multivalent Vaccines Growth Rate by Regions
- 2.2.1 Global Multivalent Vaccines Sales by Regions
- 2.2.2 Global Multivalent Vaccines Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Multivalent Vaccines Sales by Manufacturers
- 3.1.1 Multivalent Vaccines Sales by Manufacturers
- 3.1.2 Multivalent Vaccines Sales Market Share by Manufacturers
- 3.1.3 Global Multivalent Vaccines Market Concentration Ratio (CR5 and HHI)
- 3.2 Multivalent Vaccines Revenue by Manufacturers
- 3.2.1 Multivalent Vaccines Revenue by Manufacturers (2014-2019)
- 3.2.2 Multivalent Vaccines Revenue Share by Manufacturers (2014-2019)
- 3.3 Multivalent Vaccines Price by Manufacturers
- 3.4 Multivalent Vaccines Manufacturing Base Distribution, Product Types
- 3.4.1 Multivalent Vaccines Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Multivalent Vaccines Product Type
- 3.4.3 Date of International Manufacturers Enter into Multivalent Vaccines Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Multivalent Vaccines Sales by Product
- 4.2 Global Multivalent Vaccines Revenue by Product
- 4.3 Multivalent Vaccines Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Multivalent Vaccines Breakdown Data by End User
6 North America
- 6.1 North America Multivalent Vaccines by Countries
- 6.1.1 North America Multivalent Vaccines Sales by Countries
- 6.1.2 North America Multivalent Vaccines Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Multivalent Vaccines by Product
- 6.3 North America Multivalent Vaccines by End User
7 Europe
- 7.1 Europe Multivalent Vaccines by Countries
- 7.1.1 Europe Multivalent Vaccines Sales by Countries
- 7.1.2 Europe Multivalent Vaccines Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Multivalent Vaccines by Product
- 7.3 Europe Multivalent Vaccines by End User
8 Asia Pacific
- 8.1 Asia Pacific Multivalent Vaccines by Countries
- 8.1.1 Asia Pacific Multivalent Vaccines Sales by Countries
- 8.1.2 Asia Pacific Multivalent Vaccines Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Multivalent Vaccines by Product
- 8.3 Asia Pacific Multivalent Vaccines by End User
9 Central & South America
- 9.1 Central & South America Multivalent Vaccines by Countries
- 9.1.1 Central & South America Multivalent Vaccines Sales by Countries
- 9.1.2 Central & South America Multivalent Vaccines Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Multivalent Vaccines by Product
- 9.3 Central & South America Multivalent Vaccines by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Multivalent Vaccines by Countries
- 10.1.1 Middle East and Africa Multivalent Vaccines Sales by Countries
- 10.1.2 Middle East and Africa Multivalent Vaccines Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Multivalent Vaccines by Product
- 10.3 Middle East and Africa Multivalent Vaccines by End User
11 Company Profiles
- 11.1 GlaxoSmithKline, plc (U.K.)
- 11.1.1 GlaxoSmithKline, plc (U.K.) Company Details
- 11.1.2 Company Business Overview
- 11.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Products Offered
- 11.1.5 GlaxoSmithKline, plc (U.K.) Recent Development
- 11.2 Pfizer, Inc. (U.S.)
- 11.2.1 Pfizer, Inc. (U.S.) Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Pfizer, Inc. (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Pfizer, Inc. (U.S.) Multivalent Vaccines Products Offered
- 11.2.5 Pfizer, Inc. (U.S.) Recent Development
- 11.3 Merck & Co., Inc. (U.S.)
- 11.3.1 Merck & Co., Inc. (U.S.) Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Merck & Co., Inc. (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Merck & Co., Inc. (U.S.) Multivalent Vaccines Products Offered
- 11.3.5 Merck & Co., Inc. (U.S.) Recent Development
- 11.4 Sanofi Pasteur SA (France)
- 11.4.1 Sanofi Pasteur SA (France) Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Sanofi Pasteur SA (France) Multivalent Vaccines Products Offered
- 11.4.5 Sanofi Pasteur SA (France) Recent Development
- 11.5 Astellas Pharma Inc. (Japan)
- 11.5.1 Astellas Pharma Inc. (Japan) Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Products Offered
- 11.5.5 Astellas Pharma Inc. (Japan) Recent Development
- 11.6 CSL Limited (Australia)
- 11.6.1 CSL Limited (Australia) Company Details
- 11.6.2 Company Business Overview
- 11.6.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 CSL Limited (Australia) Multivalent Vaccines Products Offered
- 11.6.5 CSL Limited (Australia) Recent Development
- 11.7 Emergent BioSolutions, Inc. (U.S.)
- 11.7.1 Emergent BioSolutions, Inc. (U.S.) Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Products Offered
- 11.7.5 Emergent BioSolutions, Inc. (U.S.) Recent Development
- 11.8 Johnson & Johnson (U.S.)
- 11.8.1 Johnson & Johnson (U.S.) Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Johnson & Johnson (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Johnson & Johnson (U.S.) Multivalent Vaccines Products Offered
- 11.8.5 Johnson & Johnson (U.S.) Recent Development
- 11.9 MedImmune, LLC (U.S.)
- 11.9.1 MedImmune, LLC (U.S.) Company Details
- 11.9.2 Company Business Overview
- 11.9.3 MedImmune, LLC (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 MedImmune, LLC (U.S.) Multivalent Vaccines Products Offered
- 11.9.5 MedImmune, LLC (U.S.) Recent Development
- 11.10 Serum Institute of India Pvt. Ltd. (India)
- 11.10.1 Serum Institute of India Pvt. Ltd. (India) Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Products Offered
- 11.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Development
- 11.11 Bavarian Nordic (Denmark)
- 11.12 Mitsubishi Tanabe Pharma Corporation (Japan)
- 11.13 Daiichi Sankyo (Japan)
- 11.14 Protein Sciences Corporation (U.S.)
- 11.15 Panacea Biotec (India)
12 Future Forecast
- 12.1 Multivalent Vaccines Market Forecast by Regions
- 12.1.1 Global Multivalent Vaccines Sales Forecast by Regions 2019-2025
- 12.1.2 Global Multivalent Vaccines Revenue Forecast by Regions 2019-2025
- 12.2 Multivalent Vaccines Market Forecast by Product
- 12.2.1 Global Multivalent Vaccines Sales Forecast by Product 2019-2025
- 12.2.2 Global Multivalent Vaccines Revenue Forecast by Product 2019-2025
- 12.3 Multivalent Vaccines Market Forecast by End User
- 12.4 North America Multivalent Vaccines Forecast
- 12.5 Europe Multivalent Vaccines Forecast
- 12.6 Asia Pacific Multivalent Vaccines Forecast
- 12.7 Central & South America Multivalent Vaccines Forecast
- 12.8 Middle East and Africa Multivalent Vaccines Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Multivalent Vaccines Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Multivalent Vaccines . Industry analysis & Market Report on Multivalent Vaccines is a syndicated market report, published as Global Multivalent Vaccines Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Multivalent Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
